Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 801–900 of 1,008
Walz, C., Curtis, C., Schnittger, S., Schultheis, B. S., Metzgeroth, G., Schoch, C., Lengfelder, E., Erben, P., Müller, M. C., Haferlach, T., et al. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20359 · Cited by 77
“mately leading to imatinib-resistance (Gorre et al., 2001; Hochhaus et al., 2002).”
BackgroundInfluentialProtein tyrosine kinases: autoregulation and small-molecule inhibition
Hubbard, S. R. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00383-4 · Cited by 91
Poláková, K. M., Kulvait, V., Benesova, A., Linhartová, J., Klamová, H., Jaruskova, M., Benedittis, C. D., Haferlach, T., Baccarani, M., Martinelli, G., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1845-6 · Cited by 76
“Still, up to 20–30 % of patients develop resistance due to additional mutagenesis of BCR-ABL1 that impairs inhibitor binding (Gorre et al. 2001; Soverini et al. 2011).”
BackgroundCheong, J., Chong, S. Y., Kim, J. Y., Eom, J.-I., Jeung, H. K., Maeng, H. M., Lee, S., & Min, Y. H. (2003) · PubMed · Cited by 85
Evolution of Therapies for Chronic Myelogenous Leukemia
Santos, F. P. S., Kantarjian, H. M., Quintás‐Cardama, A., & Cortes, J. E. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823dec8d · Cited by 83
D’Avolio, A., Simiele, M., Francia, S. D., Ariaudo, A., Baietto, L., Cusato, J., Fava, C., Saglio, G. N., Carlo, F. D., & Perri, G. D. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.10.003 · Cited by 76
“protein and to a reactivation of the BCR-ABL kinase activity [9-10].”
BackgroundNelson, E. A., Sharma, S. V., Settleman, J. E., & Frank, D. A. (2011) · Oncotarget · doi:10.18632/oncotarget.296 · Cited by 80
“Some patients cannot tolerate the side effects from kinase inhibitors [9], and in others mutations arise in BCR/ABL rendering it resistant to the effect of kinase inhibitors [10].”
BackgroundBunney, T. D., Wan, S., Thiyagarajan, N., Sutto, L., Williams, S. V., Ashford, P., Koss, H., Knowles, M. A., Gervasio, F. L., Coveney, P. V., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.009 · Cited by 79
“…M a nu s c r i p t s E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s tyrosine kinase (BCR-ABL) fusion in chronic myelogenous leukaemia (Gorre et al., 2001; Shah et al., 2002), EGFR in nonsmall cell lung cancer (Kobayashi et al., 2005; Pao et al., 2005), platelet-derived growth factor…”
Chen, M., Gallipoli, P., DeGeer, D., Sloma, I., Forrest, D. L., Chan, M. M. K., Lai, D., Jørgensen, H. G., Ringrose, A., Wang, H. M., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt006 · Cited by 76
Réa, D., Legros, L., Raffoux, E., Thomas, X., Turlure, P., Maury, S., Dupriez, B., Pigneux, A., Choufi, B., Reman, O., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404115 · Cited by 79
Scheuring, U. J., Pfeifer, H., Waßmann, B., Bruck, P. T., Atta, J., Petershofen, E. K., Gehrke, B., Gschaidmeier, H., Hoelzer, D. F., & Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2002-02-0360 · Cited by 77
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells
Mukai, M., Che, X., Furukawa, T., Sumizawa, T., Aoki, S., Ren, X., Haraguchi, M., Sugimoto, Y., Kobayashi, M., Takamatsu, H., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01482.x · Cited by 81
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study
Pricl, S., Fermeglia, M., Ferrone, M. L., & Tamborini, E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0101 · Cited by 81
“This mutation, when engineered into wild-type (WT) p210 and transiently infected into 293T cells or Ba/F3 cells, interfered with the inhibition of Bcr-Abl kinase activity in cells exposed to imatinib (14, 18).”
BackgroundGatto, S., Scappini, B., Pham, L., Onida, F., Milella, M., Ball, G., Ricci, C., Divoký, V., Verstovšek, S., Kantarjian, H. M., et al. (2003) · PubMed · Cited by 84
FoxO tumor suppressors and BCR–ABL-induced leukemia: A matter of evasion of apoptosis
Jagani, Z., Singh, A. J., & Khosravi‐Far, R. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.003 · Cited by 84
“A further revelation that BCR-ABL is critical in CML comes from the determination that clinical resistance to imatinib can arise either through BCR-ABL gene amplification or point mutations within BCR-ABL [22].”
BackgroundWang, H., Yu, J., Zhang, L., Xiong, Y., Chen, S., Xing, H., Tian, Z., Tang, K., Wei, H., Rao, Q., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.086 · Cited by 75
Fusion tyrosine kinases: a result and cause of genomic instability
Penserga, E. T. P., & Skórski, T. (2006) · Oncogene · doi:10.1038/sj.onc.1209756 · Cited by 82
“…ABL kinase may increase at the accelerated phase and blast crisis, or accompany resistance to imatinib Oncogene mesylate (IM) (Gaiger et al., 1995; Gorre et al., 2001; Yamamoto et al., 2004); therefore, it seems reasonable to speculate that at the later stages of the disease high levels of…”
BackgroundIdentification of midkine as a mediator for intercellular transfer of drug resistance
Mirkin, B. L., Clark, S. H., Zheng, X. S., Chu, F., White, B. D., Greene, M. E., & Rebbaa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208671 · Cited by 81
“Dysregulation of membrane transport proteins and cellular enzymes (Gottesman et al., 1995), drug targets (Gorre et al., 2001), and altered susceptibility to commit apoptosis (Schmitt et al., 1997; Fulda and Debatin, 2003; Debatin and Krammer, 2004) are among the mechanisms believed to contribute to…”
BackgroundBRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
Jaspers, J. E., Sol, W., Kersbergen, A. J., Schlicker, A., Guyader, C., Xu, G., Wessels, L. F. A., Borst, P., Jonkers, J., & Rottenberg, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0839 · Cited by 81
“Mechanisms can be drug-specific, such as imatinib resistance caused by mutations in or overexpression of the drug target BCR–ABL (2), or downregulation of Top1 or Top2 causing resistance to topoisomerase I or II poisons (3).”
BackgroundBhatia, S., Diedrich, D., Frieg, B., Ahlert, H., Stein, S., Bopp, B., Lang, F., Zang, T., Kröger, T., Ernst, T., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810986 · Cited by 83
Tipping, A. J., Deininger, M. W., Goldman, J. M., & Melo, J. V. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.08.006 · Cited by 75
Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity
Newcomb, E. W. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000127332.06439.47 · Cited by 82
Ricci, C., Scappini, B., Divoký, V., Gatto, S., Onida, F., Verstovšek, S., Kantarjian, H. M., & Beran, M. (2002) · PubMed · Cited by 75
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
Stagno, F., Stella, S., Spitaleri, A., Pennisi, M. S., Raimondo, F. D., & Vigneri, P. G. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1151356 · Cited by 74
“of point mutations in the ABL moiety of the BCR-ABL gene is most commonly associated with IM failure [14,25,27,29,34].”
BackgroundThe evolution and expression of virulence
Ebert, D., & Bull, J. J. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199207466.003.0012 · Cited by 83
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
Lee, H., Novitzky‐Basso, I., & Kim, D. D. H. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03126-6 · Cited by 82
“However, various mutations in ABL1 kinase domain have been found conferring resistance to imatinib [31].”
BackgroundChronic Myeloid Leukaemia in The 21st Century-1
Frazer, R., Irvine, A. E., & McMullin, M. F. (2011) · PubMed Central · doi:10.6084/m9.figshare.18291 · Cited by 109
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold
Huang, Y., Henriques, S. T., Wang, C. K. L., Thorstholm, L., Daly, N. L., Kaas, Q., & Craik, D. J. (2015) · Scientific Reports · doi:10.1038/srep12974 · Cited by 74
Clinicopathological Features and Outcome for Dogs with Mast Cell Tumors and Bone Marrow Involvement
Marconato, L., Bettini, G., Giacoboni, C., Romanelli, G., Cesari, A., Zatelli, A., & Zini, E. (2008) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2008.0128.x · Cited by 74
“In human medicine, resistance to imatinib is a major concern and is believed to be caused by mutations in the kinase domain interfering with imatinib binding.(42) In addition, imatinib is a substrate of P-glycoprotein, a drug efflux pump that is highly expressed in hematopoietic stem cells, leading to low intracellula…”
BackgroundHuang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 78
“Acquired resistance to tyrosine kinase inhibitors due to secondary mutations are common (Choi et al., 2010; Gorre et al., 2001; Greger et al., 2012; Pao et al., 2005a).”
BackgroundAllosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase
Iacob, R. E., Zhang, J., Gray, N. S., & Engen, J. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015929 · Cited by 73
“Note that we have used Abl 1b numbering [45] throughout this work; for example, Abl position T315 is actually T334 in Abl 1b, but we are using the numbering designation of T315I according to the established clinical conventions [10].”
MethodDosimetry for Radiopharmaceutical Therapy
Sgouros, G., & Hobbs, R. F. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.03.007 · Cited by 87
FLT3 Tyrosine Kinase Inhibitors
Levis, M. J., & Small, D. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05079 · Cited by 78
“However, the recent experience of the numerous imatinib-resistant point mutations that have been identified in BCR:ABL transcripts from CML patients [ 42 ,43] confirms the remarkable genetic plasticity of leukemia.”
BackgroundNicolini, F. E., Hayette, S., Corm, S., Bachy, E., Bories, D., Tulliez, M., Guilhot, F., Legros, L., Maloisel, F., Kiladjian, J., et al. (2007) · Haematologica · doi:10.3324/haematol.11369 · Cited by 74
Persson, F., Winnes, M., Andrén, Y., Wedell, B., Dahlenfors, R., Asp, J., Mark, J., Enlund, F., & Stenman, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210961 · Cited by 75
“Copy number gains or amplifications of gene fusions are very rare and have previously been observed only in a few types of neoplasms, including chronic myeloid leukemia with BCR–ABL fusions (Gorre et al., 2001; Johansson et al., 2002).”
Eck, M. J., & Manley, P. W. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.014 · Cited by 80
Pene-Dumitrescu, T., & Smithgall, T. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090043 · Cited by 73
Lee, S. M., Bae, J. H., Kim, M. J., Lee, H. S., Lee, M. K., Chung, B., Kim, D. W., Kang, C., & Kim, S. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124461 · Cited by 80
“It has been suggested that resistance to imatinib stems from Bcr-Abl gene amplification, leading to overexpression of Bcr-Abl protein or point mutations in the Bcr-Abl gene (le Coutre et al., 2000; Gorre et al., 2001; Shah et al., 2002).”
BackgroundGuillamo, J.-S., de Boüard, S., Valable, S., Marteau, L., Leuraud, P., Marie, Y., Poupon, M.-F., Parienti, J.-J., Raymond, E., & Peschanski, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2042 · Cited by 72
Suppression of leukemia development caused by PTEN loss
Guo, W., Schubbert, S., Chen, J. Y., Valamehr, B., Mosessian, S., Shi, H., Dang, N. H., Garcia, C., Theodoro, M. F., Varella-Garcia, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006937108 · Cited by 70
“Of course, we cannot rule out the possible acquisition of drug-resistant mutations (34) most notably shown by characterization of Gleevec resistance in human chronic myelogenous leukemia (35).”
BackgroundTargeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 77
“This mutation was the equivalent to T315 substituion found in BCR-ABL fusion gene from CML patients with chronic yelogenous leukemia relapsed on imatinib therapy [10].”
BackgroundA Structural View on Medicinal Chemistry Strategies against Drug Resistance
Agnello, S., Brand, M., Chellat, M. F., Gazzola, S., & Riedl, R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201802416 · Cited by 74
Ghosn, Y., Kamareddine, M. H., Tawk, A., Elia, C., Mahmoud, A. E., Terro, K., Harake, N. E., Baba, B. E., Makdessi, J., & Farhat, S. G. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819853241 · Cited by 74
“However, Imatinib resistance has been described and has been associated with BCR/ABL mutations in most cases.(30,31) Resistance has also been associated with BCR/ABL amplification, high drug efflux from leukemic cells, BCR/ABL mRNA overexpression, T315I mutation, or other cytogenetic abnormalities.”
BackgroundBH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Shao, Y., & Aplin, A. E. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.94 · Cited by 76
“Similar acquired resistance has been experienced with imatinib and gefitinib and has been associated with reactivation of the drug target and/or its pathway.(20,21) In many such cases, secondary mutations within the drug target that modify drug binding or permit target activation in the presence of drug have been asso…”
BackgroundBiochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors
Krishnamurty, R., & Maly, D. J. (2010) · ACS Chemical Biology · doi:10.1021/cb9002656 · Cited by 83
7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as Dual Inhibitors of Src and Abl Kinases
Boschelli, D. H., Wang, Y. D., Johnson, S., Wu, B., Ye, F., Sosa, A. C. B., Golas, J. M., & Boschelli, F. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499458 · Cited by 72
Chu, S., Li, L., Singh, H., & Bhatia, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4312 · Cited by 82
“However, clinical resistance to IM can occur (7, 8).”
BackgroundVarley, K. E., Mutch, D. G., Edmonston, T. B., Goodfellow, P. J., & Mitra, R. D. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp457 · Cited by 78
Campbell, L. J., Patsouris, C., Rayeroux, K. C., Somana, K., Januszewicz, E. H., & Szer, J. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00615-5 · Cited by 75
McCormick, F. P. (2001) · Nature · doi:10.1038/35085665 · Cited by 75
Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases
Persky, N. S., Hernandez, D., Carmo, M. D., Brenan, L., Cohen, O., Kitajima, S., Nayar, U., Walker, A., Pantel, S., Lee, Y., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0358-z · Cited by 68
Single-cell analysis based dissection of clonality in myelofibrosis
Mylonas, E., Yoshida, K., Frick, M., Hoyer, K., Christen, F., Kaeda, J., Obenaus, M., Noerenberg, D., Hennch, C., Chan, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13892-x · Cited by 75
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Ravandi, F., & Kebriaei, P. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.07.007 · Cited by 78
“Acquired imatinib resistance may be due to BCR-ABL–dependent mechanisms such as bcr-abl overexpression or mutations in the kinase domains (KD) (Table 3).(61,62)”
BackgroundInfluentialKim, S.-H., Menon, H., Jootar, S., Saikia, T., Kwak, J., Sohn, S. K., Park, J. S., Jeong, S. H., Kim, H., Kim, Y.-K., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096776 · Cited by 71
Sillaber, C., Mayerhofer, M., Böhm, A., Vales, A., Gruze, A., Aichberger, K. J., Esterbauer, H., Pfeilstöcker, M., Sperr, W. R., Pickl, W. F., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01892.x · Cited by 75
Ma, X., Lv, X., & Zhang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.049 · Cited by 77
McLean, S. R., Gana‐Weisz, M., Hartzoulakis, B., Frow, R., Whelan, J., Selwood, D. L., & Boshoff, C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0070 · Cited by 74
Druker, B. J., Sawyers, C. L., Capdeville, R., Ford, J., Baccarani, M., & Goldman, J. M. (2001) · Hematology · doi:10.1182/asheducation-2001.1.87 · Cited by 98
Self-citationPuissant, A., Grosso, S., Jacquel, A., Belhacène, N., Colosetti, P., Cassuto, J., & Auberger, P. (2008) · The FASEB Journal · doi:10.1096/fj.07-101394 · Cited by 73
“Other mechanisms included bcr-abl gene amplification leading to the increased expression of p210 BCR-ABL (17, 18) or up-regulation of the multidrug resistance-1 (MDR-1) gene-encoded Pgp (19).”
BackgroundAbl tyrosine kinases in T‐cell signaling
Gu, J., Ryu, J. R., & Pendergast, A. M. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00751.x · Cited by 72
“The major cause of resistance is the emergence of BCR-ABL mutants that are insensitive or have reduced sensitivity to inhibition by imatinib (59, 60).”
BackgroundEGFR inhibition in the treatment of non‐small cell lung cancer
Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 74
Gastrointestinal stromal tumors–a review
Joensuu, H., & Kindblom, L. (2004) · Acta Orthopaedica Scandinavica · doi:10.1080/00016470410001708340 · Cited by 70
“New mutations, sometimes affecting the binding site of imatinib, have been described both in CML and GIST patients who have developed acquired resistance to imatinib, and the target gene amplifications may also occur in cancers resistant to imatinib (Gorre et al. 2001, Fletcher et al. 2003).”
BackgroundKoschmieder, S., & Vetrie, D. L. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.006 · Cited by 76
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli, G., Soverini, S., Rosti, G., Cilloni, D., & Baccarani, M. (2005) · PubMed · Cited by 75
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment
Roche‐Lestienne, C., & Preudhomme, C. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70025-0 · Cited by 75
BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?
Goldman, J. M., & Melo, J. V. (2008) · Acta Haematologica · doi:10.1159/000140633 · Cited by 72
“1 Table 1. A classification of known mechanisms of resistance to TKIs T01 KD Mutations In 2001, investigators in Los Angeles who studied a patient whose leukemia appeared to be resistant to imatinib discovered that the Ph-positive clone consisted predominantly of cells bearing a mutation in the KD that coded for an am…”
BackgroundWardelmann, E., Büttner, R., Merkelbach‐Bruse, S., & Schildhaus, H. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0473-9 · Cited by 70
“Several different new mutations in addition to the primary mutation may occur indicating polyclonal resistance as already shown in chronic myelogenic leukemia under imatinib treatment [4, 16].”
BackgroundDetection of ABL kinase domain mutations with denaturing high-performance liquid chromatography
Deininger, M. W., McGreevey, L. S., Willis, S. G., Bainbridge, T., Druker, B. J., & Heinrich, M. C. (2004) · Leukemia · doi:10.1038/sj.leu.2403307 · Cited by 70
Gilmer, T. M., Cable, L., Alligood, K. J., Rusnak, D. W., Spehar, G. M., Gallagher, K. T., Woldu, E., Carter, H. L., Truesdale, A. T., Shewchuk, L. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2404 · Cited by 70
Yu, C., Subler, M. A., Rahmani, M., Reese, E., Krystal, G. W., Conrad, D. H., Dent, P., & Grant, S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.454 · Cited by 79
Recent Advancements in the Treatment of Chronic Myelogenous Leukemia
O'Dwyer, M. E., Mauro, M. J., & Druker, B. J. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103853 · Cited by 72
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
Chandra, J., Hackbarth, J. S., Le, S. B., Loegering, D. A., Bone, N. D., Bruzek, L. M., Narayanan, V. L., Adjei, A. A., Kay, N. E., Tefferi, A., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0562 · Cited by 73
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
Jørgensen, H. G., Allan, E. K., Graham, S. M., Godden, J., Richmond, L., Elliott, M. A., Mountford, J. C., Eaves, C. J., & Holyoake, T. L. (2005) · Leukemia · doi:10.1038/sj.leu.2403785 · Cited by 70
Sliding-Window Thompson Sampling for Non-Stationary Settings
Trovò, F., Paladino, S., Restelli, M., & Gatti, N. (2020) · Journal of Artificial Intelligence Research · doi:10.1613/jair.1.11407 · Cited by 107
Targeting Gatekeeper Mutations for Kinase Drug Discovery
Zhou, Y., Xiang, S., Yang, F., & Lu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01361 · Cited by 71
Kamal, Ä., Dastagiri, D., Ramaiah, M. J., Reddy, J., Bharathi, E. V., Reddy, M. K., Sagar, M. V. P., Reddy, T. L., Pushpavalli, S. N. C. V. L., & Pal‐Bhadra, M. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.039 · Cited by 69
Castagnetti, F., Palandri, F., Amabile, M., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Breccia, M., Cambrin, G. R., Stagno, F., et al. (2009) · Blood · doi:10.1182/blood-2007-08-103499 · Cited by 74
Herrmann, H., Cerny-Reiterer, S., Gleixner, K. V., Blatt, K., Herndlhofer, S., Rabitsch, W., Jager, E., Mitterbauer-Hohendanner, G., Streubel, B., Selzer, E., et al. (2012) · Haematologica · doi:10.3324/haematol.2010.035006 · Cited by 67
“4 f 48 BP 46,XX,del(7),der(8)t(7;8),t(9;22),t(9;2;16) G250E 73.”
BackgroundInfluentialWhite, D. L., Saunders, V. A., Grigg, A., Arthur, C., Filshie, R., Leahy, M. F., Lynch, K., To, L. B., & Hughes, T. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9499 · Cited by 74
Eadie, L. N., Dang, P. G., Saunders, V. A., Yeung, D. T. O., Osborn, M. P., Grigg, A., Hughes, T. P., & White, D. L. (2016) · Leukemia · doi:10.1038/leu.2016.179 · Cited by 69
Harnessing preclinical mouse models to inform human clinical cancer trials
Gutmann, D. H., Hunter‐Schaedle, K., & Shannon, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28271 · Cited by 72
“Furthermore, the emergence of imatinib-resistant mutant alleles of BCR-ABL in patients with chronic myeloid leukemia (59, 60) argues strongly that the cancer-initiating mutation remains central to the tumor’s growth advantage.”
Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.004 · Cited by 68
Managing resistance in chronic myeloid leukemia
Roychowdhury, S., & Talpaz, M. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.09.001 · Cited by 69
“In the remaining eight patients, they identified point mutations in the Abl kinase domain that resulted in amino acid substitutions and conferred resistance to imatinib in vitro.(17) Kinase domain mutations can confer resistance through changes in the ATP-binding loop (P-loop) that limit protein conformation and alter…”
BackgroundLyczek, A., Berger, B.-T., Rangwala, A. M., Paung, Y., Tom, J., Philipose, H., Guo, J., Albanese, S. K., Robers, M. B., Knapp, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111451118 · Cited by 68
Targeting lysine acetylation readers and writers
Zhou, M., & Cole, P. A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01080-6 · Cited by 75
“For example, mutations arising in the Bcr-Abl tyrosine kinase onco-gene can limit the effects of imatinib 218 .”
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
Klawitter, J., Kominsky, D. J., Brown, J. L., Klawitter, J., Christians, U., Leibfritz, D., Melo, J. V., Eckhardt, S., & Serkova, N. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00345.x · Cited by 68
“Imatinib is able to control CML in the majority of the patients, but primary or secondary resistance to the inhibitor is matter of concern (Gorre et al., 2001; Melo and Chuah, 2007).”
BackgroundDetection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
Branford, S., & Hughes, T. P. (2006) · Humana Press eBooks · doi:10.1385/1-59745-017-0:93 · Cited by 78
Weisberg, E., Choi, H. G., Ray, A., Barrett, R., Zhang, J., Sim, T., Zhou, W., Seeliger, M. A., Cameron, M. D., Azam, M., et al. (2010) · Blood · doi:10.1182/blood-2009-11-251751 · Cited by 68
Mustjoki, S. M., Richter, J. R., Barbany, G., Ehrencrona, H., Fioretos, T., Gedde‐Dahl, T., Gjertsen, B. T., Hovland, R., Hernesniemi, S., Josefsen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.19 · Cited by 68
KLF4 suppresses transformation of pre-B cells by ABL oncogenes
Kharas, M. G., Yusuf, I., Scarfone, V. M., Yang, V. W., Segre, J. A., Huettner, C. S., & Fruman, D. A. (2006) · Blood · doi:10.1182/blood-2006-03-011106 · Cited by 68
Tanaka, R., Squires, M. S., Kimura, S. H., Yokota, A., Nagao, R., Yamauchi, T., Takeuchi, M., Yao, H., Reule, M., Smyth, T., et al. (2010) · Blood · doi:10.1182/blood-2009-03-211466 · Cited by 73
“Among several mechanisms of resistance, point mutations within the ABL kinase domain that interfere with imatinib binding are the most critical cause of imatinib resistance.(4,5)”
BackgroundKurokawa, M., Kim, J., Geradts, J., Matsuura, K., Liu, L., Xu, R., Xia, W., Ribar, T. J., Henao, R., Dewhirst, M. W., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003741 · Cited by 75
“Therapeutic resistance can result from mutations in the tyrosine kinase itself (for example, imatinib-resistance stemming from mutation of Bcr-Abl in chronic myeloid leukemias), but this is not always the case (11, 12).”
BackgroundLovera, S., Morando, M. A., Pucheta-Martínez, E., Martinez-Torrecuadrada, J. L., Saladino, G., & Gervasio, F. L. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004578 · Cited by 69
“In the case of the widely studied “gatekeeper”mutant, found in several TKs (T315I in Abl) [9], three mechanisms have been proposed.”
BackgroundCarlisi, D., Blasio, A. D., Drago‐Ferrante, R., Fiore, R. D., Buttitta, G., Morreale, M., Scerri, C. A., Vento, R., & Tesoriere, G. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.78 · Cited by 73
Deininger, M. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5015 · Cited by 70
Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity
Xu, R., Dong, Q., Yu, Y., Zhao, X., Gan, X., Wu, D., Lu, Q., Xu, X., & Yu, X.-F. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.05.023 · Cited by 74
The biology of signal transduction inhibition: Basic science to novel therapies
Griffin, J. D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90097-1 · Cited by 71
Controlling Abl: auto-inhibition and co-inhibition?
Wang, J. Y. J. (2004) · Nature Cell Biology · doi:10.1038/ncb0104-3 · Cited by 67
“With advanced CML, however, resistance to Gleevec readily emerges as a result of re-activation of BCR-Abl kinase through overproduction or mutatio”
BackgroundMechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 73
Sharma, S. V., & Settleman, J. E. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.026 · Cited by 75
“This mutation, which arises at a position analogous to the T315 position in the ABL kinase domain, and which undergoes substitution to isoleucine in a large fraction of CML patients with acquired imatinib resistance [121], is the so-called bgatekeeperQ residue [122].”
Background
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.